Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + radiotherapy + androgen deprivation therapy
- Development stage
- Unknown
- Lead developer
- Medical University of South Carolina
- Modality
- Small Molecules
- Administration
- Intravenous, Subcutaneous, Intramuscular
01
Overview
This therapeutic regimen consists of the taxane chemotherapy agent docetaxel administered weekly in combination with definitive radiotherapy and long-term androgen deprivation therapy (ADT). Developed and studied by the Medical University of South Carolina (MUSC), this multimodal combination is intended for patients with high-risk localized prostate cancer. Docetaxel acts by stabilizing microtubules, thereby inhibiting cell division and inducing apoptosis. Radiotherapy provides local control by inducing DNA damage, while ADT reduces circulating testosterone levels to inhibit the growth of androgen-sensitive prostate cancer cells. The Phase I study (NCT00115310) aimed to determine the maximum tolerated dose of weekly docetaxel when integrated into this treatment framework to improve outcomes in high-risk localized disease.
- Brand names
- Taxotere
- Other names
- Taxotere with radiation and hormone therapyWeekly docetaxel with radiotherapy and ADTDocetaxel-based chemo-radiotherapy and hormone therapy
02
Targets
TUBB (Tubulin (alpha and beta subunits))GnRHR (Gonadotropin-releasing hormone receptor)AR (Adrenergic receptors)DNA
Beyond the preview
Go deeper on docetaxel + radiotherapy + androgen deprivation therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + radiotherapy + androgen deprivation therapy.